BGBIO Bergenbio ASA

Edison Investment Research Limited: BerGenBio (BGBIO): Advancing towards pivotal studies

Edison Investment Research Limited
Edison Investment Research Limited: BerGenBio (BGBIO): Advancing towards pivotal studies

23-Aug-2021 / 07:00 GMT/BST

 

London, UK, 23 August 2021

 

BerGenBio (BGBIO): Advancing towards pivotal studies

BerGenBio (BGBIO) has made continued progress in H121 in advancing the development of lead asset bemcentinib (an oral, once-a-day, highly selective AXL inhibitor). A deluge of data presentations from Phase II studies in COVID-19, AML and NSCLC continue to highlight the broad potential of this first-in-class treatment. Discussions with regulators are ongoing regarding a pivotal study in relapsed AML in combination with LDAC, which could enable potential approval and launch in 2024. COVID-19 presents a potential opportunity to expedite bemcentinib's route to market in 2022. Discussions with regulators will determine the next steps following top-line data from two Phase II trials. We value BGBIO at NOK4.91bn.

 

We value BGBIO at NOK4.91bn or NOK 55.8/share vs NOK4.72bn or NOK53.8/ share previously. We have rolled forward our model and reflect net cash of NOK572.8m at 30 June 2021. We have updated our financial forecasts to reflect H121 results and increased R&D expenses (FY21: NOK228.8m vs NOK205.9m, FY22: NOK233.4m vs NOK216.2m) due to growing clinical trial activities.


to view the full report or to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Dr John Priestner +44 (0)20 3077 5700

Dr Susie Jana +44 (0)20 3077 5700

Learn more at and connect with Edison on: 

LinkedIn       

Twitter          

YouTube      


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

1227971  23-Aug-2021 

fncls.ssp?fn=show_t_gif&application_id=1227971&application_name=news&site_id=research_pool
EN
23/08/2021

Underlying

BGBIOBergenbio ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bergenbio ASA

Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
BGBIO BERGENBIO ASA

BerGenBio (No_rec, TP: NOK) - Decision to end BGBC016 trial – recommen...

BerGenBio announced yesterday that it has decided to discontinue its 1L STK11m NSCLC trial due to the weak preliminary results. We already believed the value of the data would be limited, but this is a significant setback for the company. BerGenBio said that it is entering a new phase, in which strategic alternatives will be explored. As a result of the trial discontinuation, the company’s financial situation, and limited available information on the potential alternatives being explored, we hav...

02/26/25 February 26, 2025 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
BGBIO BERGENBIO ASA

BerGenBio (Sell, TP: NOK5.00) - Decision to end BGBC016 trial

BerGenBio announced tonight that it has decided to discontinue its 1L STK11m NSCLC trial due to preliminary results not being strong enough. We already believed the value of the data would be limited, and this is a significant setback for the company. The company said that it is now entering a new phase in which strategic alternatives will be explored.

02/25/25 February 25, 2025 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
BGBIO BERGENBIO ASA

BerGenBio (Sell, TP: NOK5.00) - Q2 report

BerGenBio said that its BGBC016 trial is progressing as planned, with all sites in the phase IIa part activated. It expects a phase IIa interim analysis at end-2024. We reiterate our SELL and NOK5 target price.

08/26/24 August 26, 2024 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
BGBIO BERGENBIO ASA

BerGenBio (Sell, TP: NOK0.05) - Q1 report

While the Q1 report contained no large surprises, the company announced earlier this week a clinical collaboration with UT Health San Antonio and Sobi to evaluate bemcentinib in combination with Sobi’s pacritinib in patients with advanced lung adenocarcinoma. We reiterate our SELL and NOK0.05 target price on our concerns about the company’s ability to generate sufficient investor interest during its financial runway and ahead of the next need for financing.

05/30/24 May 30, 2024 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
BGBIO BERGENBIO ASA

BerGenBio (Sell, TP: NOK0.05) - Our concerns remain

While opex fell sharply in 2023 and YOY in Q4, and management maintained the timeline for its BGBC016 study, we remain concerned about a lack of major share-price catalysts ahead of the next needed capital raise. We reiterate our SELL and NOK0.05 target price.

02/25/24 February 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch